Sentinel lymph node biopsy in breast cancer guided by CT lymphography; History, evolution and current applications

2021 ◽  
pp. 1-7
Author(s):  
Omar Hamdy ◽  
Omar Farouk ◽  
Adel El-Badrawy ◽  
Adel Denewer ◽  
Ahmed Setit

Sentinel lymph node biopsy (SLNB) has efficiently replaced axillary lymph node dissection (ALND) in axillary staging in node-negative breast cancer patients. Dual sentinel lymph node (SLN) localization using radioisotopes and blue dye is the standard technique for SLN mapping. Yet, nuclear medicine facilities are not widely available worldwide. In Japan, Computed tomography lymphography (CTLG) is presented as an SLN mapping technique which was first suggested in 2003 by Suga et al. Multiple subsequent studies confirmed the efficacy of CTLG in SLN mapping in breast cancer. Further applications of the technique followed; such as prediction of SLN metastasis using CTLG, the use of CTLG guided SLN biopsy after neoadjuvant therapy, video-assisted CTLG guided SLN biopsy, the use of real-time virtual sonography with 3-D CTLG, and preoperative localization of the CTLG mapped SLN using either real-time virtual sonography (RVS) guided Indocyanine green (ICG) injection or its marking using liquid charcoal and silver wire and the use of SPIO enhanced magnetic resonance imaging (MRI) for prediction of metastasis in SLNs detected by CTLG. This efficacy and variable applications open the door for conducting wide-scale randomized controlled trials to suggest using CTLG as an efficient alternative for the use of radioisotopes in SLN mapping in breast cancer patients, especially in low and middle-income countries.

2006 ◽  
Vol 72 (10) ◽  
pp. 939-942
Author(s):  
David K. Rosing ◽  
Christine E. Dauphine ◽  
M. Perla Vargas ◽  
Katherine Gonzalez ◽  
Melissa Burla ◽  
...  

The accuracy of sentinel lymph node biopsy (SLNB) staging in breast cancer has been demonstrated in studies comparing it with axillary dissection. There is a 5 per cent false-negative rate, but this does not always correlate with axillary recurrence. Our purpose was to determine the rate of axillary lymphatic recurrence in breast cancer patients who had a negative SLNB. We conducted a cohort study of breast cancer patients who underwent SLNB between 2001 and 2005. Only patients who had a negative SLNB were included. Patient demographics and tumor factors were reviewed. Outcomes measured were axillary and systemic recurrence and survival. Eighty-nine patients with a mean age of 54.4 ± 9.9 years were included. Eighty-nine per cent of cases had infiltrating ductal carcinoma histology. Mean tumor size was 19 ± 14 mm. Breast conservation surgery was done in 65 cases and mastectomy in 24. A mean of 2.3 ± 2.4 SLN were found. After a median follow-up of 2.15 years, 1 (1%) patient developed a lymphatic recurrence in the axilla. SLNB provides accurate staging of breast cancer. Patients with negative SLNB do not require axillary dissection.


Cancer ◽  
2011 ◽  
Vol 117 (20) ◽  
pp. 4606-4616 ◽  
Author(s):  
Vaclav Pecha ◽  
Dusan Kolarik ◽  
Renata Kozevnikova ◽  
Karolina Hovorkova ◽  
Petruse Hrabetova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document